Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epilepsy: A randomized response conditional cross-over study

Epilepsy Research

Volumn 25, Issue 3, 1996, Pages 257-262

  Tanganelli, Paolo ^a   Regesta, Giovanni ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

carbamazepine; monotherapy; newly diagnosed epilepsy; vigabatrin

Indexed keywords

CARBAMAZEPINE; VIGABATRIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPLEX PARTIAL SEIZURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIPLOPIA; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; LEUKOPENIA; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; VERTIGO;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CARBAMAZEPINE; CROSS-OVER STUDIES; EPILEPSY, COMPLEX PARTIAL; FEMALE; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MIDDLE AGED; VIGABATRIN;

EID: 0030297101     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(96)00074-5     Document Type: Article

References (12)

1. [1] Browne, T.R., Mattson, R.H., Penry, J.K. et al., Multicenter long-term safety and efficacy study of vigabatrin for refractory complex partial seizures: an update, Neurology, 41 (1991) 363-364.
2. [2] Cocito, L., Maffini, M., Perfumo, P., Roncallo, F. and Loeb, C., Vigabatrin in complex partial seizures: a long-term study, Epilepsy Res., 3 (1989) 160-166.
3. [3] Engel, Jr., J., Bandler, R., Griffith, N.G. and Caldecott-Hazard, S., Neurobiological evidence for epilepsy-induced interictal disturbances. In: D.B. Smith, D.M. Treiman and M.R. Trimble (Eds.), Neurobehavioral Problems in Epilepsy, Raven Press, New York, 1991, pp. 97-111.
4. [4] Engel, Jr., J., The progressive nature of epilepsy. In: Am. Acad. Neurology Annual Course, Vol. 1, Section 324, American Academy of Neurology, 1993, pp. 1-11.
5. [5] Kalvïaïnen, R., Aikia, M., Saukkonen, A.M. et al., Vigabatrin vs. carbamazepine monotherapy in patients with newly diagnosed epilepsy. A randomized, controlled study, Arch. Neurol, 52 (1995) 989-996.
6. [6] Michelucci, R., Tassinari, C.A., Iudice, A. and Mumford, J.P., Efficacia a lungo termine del vigabatrin nel'epilessia farmaco-resistente, Boll. Lega Ital. Epil., 62/63 (1988) 393-394.
7. [7] Pedersen, S.A., Klosterskov, P., Gram, L. and Dam, M., Long-term study of gamma-vinyl GABA in the treatment of epilepsy, Acta Neurol. Scand., 72 (1985) 295-298.
8. [8] Sivenius, J., Ylinen, A., Murros, K. et al., Vigabatrin in drug-resistant partial epilepsy: a 5 year follow-up study, Neurology, 41 (1991) 562-565.
9. [9] Tanganelli, P., Ottonello, G.A. and Regesta, G., Vigabatrin vs. carbamazepine in monotherapy in newly diagnosed patients with partial epilepsy: a randomized cross-over study. Preliminary data. Boll. Lega Ital. Epil., 82/83 (1993) 137-138.
10. [10] Tanganelli, P. and Regesta, G., Vigabatrin vs. carbamazepine monotherapy in newly diagnosed focal epileptics: a randomized response conditional cross-over study. In: European Congress of Epileptology, Oporto, Portugal, Epilepsia, 35, Suppl. 7 (1994) abst. 65.
11. [11] Tartara, A., Manni, R., Galimberti, C.A. et al., Vigabatrin in the treatment of epilepsy: a long-term follow-up study, J. Neurol. Neurosurg. Psychiat., 52 (1989) 467-471.
12. [12] Troupin, A.S., Antiepileptic drug therapy: a clinical review. In: E. Wyllie (Ed.), The Treatment of Epilepsy: Principles and Practice, Lea and Febiger, Philadelphia, PA, 1992, pp. 785-791.